Issue navigation
Volume 54, Issue suppl_3, April 2012
Oritavancin for the Treatment of Serious Gram-Positive Infections
COVER
Cover
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Page NP, https://doi.org/10.1093/cid/cis320
STANDING MATERIAL
IDSA/HIVMA Board Page
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Page NP, https://doi.org/10.1093/cid/cis321
Editorial Board
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Page NP, https://doi.org/10.1093/cid/cis322
Masthead
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Page NP, https://doi.org/10.1093/cid/cis323
Subscription Page
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Page NP, https://doi.org/10.1093/cid/cis324
Table of Contents
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Page NP, https://doi.org/10.1093/cid/cis325
Guest Editors and Sponsor
Oritavancin for the Treatment of Serious Gram-Positive Infections
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Page NP, https://doi.org/10.1093/cid/cis326
Supplement Articles
Introduction: Solving the Clinical Problem of Vancomycin Resistance
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Pages S201–S202, https://doi.org/10.1093/cid/cir1046
Oritavancin Microbiologic Features and Activity Results From the Surveillance Program in the United States
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Pages S203–S213, https://doi.org/10.1093/cid/cir923
Oritavancin: Mechanism of Action
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Pages S214–S219, https://doi.org/10.1093/cid/cir920
In Vivo Activity of Oritavancin in Animal Infection Models and Rationale for a New Dosing Regimen in Humans
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Pages S220–S228, https://doi.org/10.1093/cid/cis001
Macrophage Killing of Bacterial and Fungal Pathogens Is Not Inhibited by Intense Intracellular Accumulation of the Lipoglycopeptide Antibiotic Oritavancin
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Pages S229–S232, https://doi.org/10.1093/cid/cir921
Unmet Needs and Prospects for Oritavancin in the Management of Vancomycin-Resistant Enterococcal Infections
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Pages S233–S238, https://doi.org/10.1093/cid/cir924
Oritavancin: A New Opportunity for Outpatient Therapy of Serious Infections
Clinical Infectious Diseases, Volume 54, Issue suppl_3, April 2012, Pages S239–S243, https://doi.org/10.1093/cid/cir1047
